vs
碧迪（BDX）与Expeditors International（EXPD）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Expeditors International的1.8倍（$5.3B vs $2.9B），碧迪净利率更高（7.3% vs 7.0%，领先0.2%），碧迪同比增速更快（-0.4% vs -3.3%），碧迪自由现金流更多（$549.0M vs $270.3M），过去两年Expeditors International的营收复合增速更高（13.8% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
美国财富500强物流服务企业，总部位于华盛顿州贝尔维尤，依托覆盖六大洲100余个国家超340个网点的全球网络及统一集成的技术系统，为客户提供高度优化的定制化供应链解决方案。
BDX vs EXPD — 直观对比
营收规模更大
BDX
是对方的1.8倍
$2.9B
营收增速更快
BDX
高出3.0%
-3.3%
净利率更高
BDX
高出0.2%
7.0%
自由现金流更多
BDX
多$278.7M
$270.3M
两年增速更快
EXPD
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $2.9B |
| 净利润 | $382.0M | $200.7M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 8.8% |
| 净利率 | 7.3% | 7.0% |
| 营收同比 | -0.4% | -3.3% |
| 净利润同比 | 24.0% | -14.9% |
| 每股收益（稀释后） | $1.34 | $1.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXEXPD
| Q4 25 | $5.3B | $2.9B | ||
| Q3 25 | $5.9B | $2.9B | ||
| Q2 25 | $5.5B | $2.7B | ||
| Q1 25 | $5.3B | $2.7B | ||
| Q4 24 | $5.2B | $3.0B | ||
| Q3 24 | $5.4B | $3.0B | ||
| Q2 24 | $5.0B | $2.4B | ||
| Q1 24 | $5.0B | $2.2B |
净利润BDXEXPD
| Q4 25 | $382.0M | $200.7M | ||
| Q3 25 | $493.0M | $222.3M | ||
| Q2 25 | $574.0M | $183.6M | ||
| Q1 25 | $308.0M | $203.8M | ||
| Q4 24 | $303.0M | $235.9M | ||
| Q3 24 | $400.0M | $229.6M | ||
| Q2 24 | $487.0M | $175.5M | ||
| Q1 24 | $537.0M | $169.2M |
毛利率BDXEXPD
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXEXPD
| Q4 25 | 10.5% | 8.8% | ||
| Q3 25 | 11.8% | 10.0% | ||
| Q2 25 | 16.0% | 9.3% | ||
| Q1 25 | 10.4% | 10.0% | ||
| Q4 24 | 8.8% | 10.2% | ||
| Q3 24 | 11.4% | 10.1% | ||
| Q2 24 | 12.1% | 9.2% | ||
| Q1 24 | 14.5% | 9.7% |
净利率BDXEXPD
| Q4 25 | 7.3% | 7.0% | ||
| Q3 25 | 8.4% | 7.7% | ||
| Q2 25 | 10.4% | 6.9% | ||
| Q1 25 | 5.8% | 7.6% | ||
| Q4 24 | 5.9% | 8.0% | ||
| Q3 24 | 7.4% | 7.7% | ||
| Q2 24 | 9.8% | 7.2% | ||
| Q1 24 | 10.6% | 7.7% |
每股收益（稀释后）BDXEXPD
| Q4 25 | $1.34 | $1.50 | ||
| Q3 25 | $1.71 | $1.64 | ||
| Q2 25 | $2.00 | $1.34 | ||
| Q1 25 | $1.07 | $1.47 | ||
| Q4 24 | $1.04 | $1.68 | ||
| Q3 24 | $1.37 | $1.63 | ||
| Q2 24 | $1.68 | $1.24 | ||
| Q1 24 | $1.85 | $1.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $1.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $25.3B | $2.4B |
| 总资产 | $54.8B | $4.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDXEXPD
| Q4 25 | $740.0M | $1.3B | ||
| Q3 25 | $641.0M | $1.2B | ||
| Q2 25 | $735.0M | $1.2B | ||
| Q1 25 | $667.0M | $1.3B | ||
| Q4 24 | $711.0M | $1.1B | ||
| Q3 24 | $1.7B | $1.3B | ||
| Q2 24 | $4.5B | $1.3B | ||
| Q1 24 | $2.3B | $1.4B |
股东权益BDXEXPD
| Q4 25 | $25.3B | $2.4B | ||
| Q3 25 | $25.4B | $2.3B | ||
| Q2 25 | $25.5B | $2.2B | ||
| Q1 25 | $25.2B | $2.3B | ||
| Q4 24 | $25.2B | $2.2B | ||
| Q3 24 | $25.9B | $2.4B | ||
| Q2 24 | $25.9B | $2.2B | ||
| Q1 24 | $25.6B | $2.2B |
总资产BDXEXPD
| Q4 25 | $54.8B | $4.9B | ||
| Q3 25 | $55.3B | $4.8B | ||
| Q2 25 | $54.9B | $4.8B | ||
| Q1 25 | $54.5B | $4.8B | ||
| Q4 24 | $54.7B | $4.8B | ||
| Q3 24 | $57.3B | $5.2B | ||
| Q2 24 | $55.6B | $4.8B | ||
| Q1 24 | $54.2B | $4.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $283.3M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $270.3M |
| 自由现金流率自由现金流/营收 | 10.5% | 9.5% |
| 资本支出强度资本支出/营收 | 2.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.72× | 1.41× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $953.4M |
8季度趋势，按日历期对齐
经营现金流BDXEXPD
| Q4 25 | $657.0M | $283.3M | ||
| Q3 25 | $1.4B | $201.4M | ||
| Q2 25 | $1.2B | $179.2M | ||
| Q1 25 | $164.0M | $342.6M | ||
| Q4 24 | $693.0M | $249.7M | ||
| Q3 24 | $1.2B | $90.0M | ||
| Q2 24 | $1.3B | $126.8M | ||
| Q1 24 | $514.0M | $256.9M |
自由现金流BDXEXPD
| Q4 25 | $549.0M | $270.3M | ||
| Q3 25 | $1.0B | $190.3M | ||
| Q2 25 | $1.0B | $163.3M | ||
| Q1 25 | $35.0M | $329.5M | ||
| Q4 24 | $588.0M | $239.7M | ||
| Q3 24 | $882.0M | $77.7M | ||
| Q2 24 | $1.1B | $118.8M | ||
| Q1 24 | $380.0M | $246.7M |
自由现金流率BDXEXPD
| Q4 25 | 10.5% | 9.5% | ||
| Q3 25 | 17.0% | 6.6% | ||
| Q2 25 | 19.0% | 6.2% | ||
| Q1 25 | 0.7% | 12.4% | ||
| Q4 24 | 11.4% | 8.1% | ||
| Q3 24 | 16.2% | 2.6% | ||
| Q2 24 | 22.4% | 4.9% | ||
| Q1 24 | 7.5% | 11.2% |
资本支出强度BDXEXPD
| Q4 25 | 2.1% | 0.5% | ||
| Q3 25 | 6.0% | 0.4% | ||
| Q2 25 | 3.2% | 0.6% | ||
| Q1 25 | 2.4% | 0.5% | ||
| Q4 24 | 2.0% | 0.3% | ||
| Q3 24 | 5.4% | 0.4% | ||
| Q2 24 | 3.6% | 0.3% | ||
| Q1 24 | 2.7% | 0.5% |
现金转化率BDXEXPD
| Q4 25 | 1.72× | 1.41× | ||
| Q3 25 | 2.75× | 0.91× | ||
| Q2 25 | 2.12× | 0.98× | ||
| Q1 25 | 0.53× | 1.68× | ||
| Q4 24 | 2.29× | 1.06× | ||
| Q3 24 | 2.94× | 0.39× | ||
| Q2 24 | 2.66× | 0.72× | ||
| Q1 24 | 0.96× | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
EXPD
| Customs Brokerage And Other Services | $1.1B | 40% |
| Airfreight Services | $1.1B | 39% |
| Ocean Freight And Ocean Services | $611.4M | 21% |
